Novartis AG
NVSEF
$106.50
-$3.64-3.30%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.15% | -66.77% | 81.09% | 40.16% | 17.23% |
| Total Depreciation and Amortization | -0.52% | 110.87% | -11.70% | -11.57% | -16.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.73% | 139.83% | -19.38% | 202.69% | -36.51% |
| Change in Net Operating Assets | 14.02% | 65.40% | -10.73% | 73.40% | -22.67% |
| Cash from Operations | 60.93% | 64.63% | 16.88% | 36.33% | -23.40% |
| Capital Expenditure | -11.89% | -37.44% | -22.99% | -15.56% | -35.12% |
| Sale of Property, Plant, and Equipment | 900.00% | -71.34% | -98.04% | 825.00% | -94.44% |
| Cash Acquisitions | -- | -7,000.00% | 98.32% | -3,193.00% | -2,310.00% |
| Divestitures | 89.47% | 8,300.00% | 250.00% | -262.50% | -192.31% |
| Other Investing Activities | 246.70% | -49.67% | -100.21% | 144.79% | -103.65% |
| Cash from Investing | 136.71% | -72.33% | 83.09% | -204.56% | -108.46% |
| Total Debt Issued | -54.43% | -104.40% | -- | -- | 22.12% |
| Total Debt Repaid | -1,510.45% | -228.13% | 57.10% | -185.40% | -1.52% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -147.13% | -119.90% | -75.63% | 45.35% | 61.92% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.42% | -- | -- | -- | 28.23% |
| Other Financing Activities | 309.09% | -428.21% | -101.23% | -126.60% | 92.81% |
| Cash from Financing | -65.53% | -393.57% | 54.09% | 12.02% | 43.88% |
| Foreign Exchange rate Adjustments | 242.86% | -296.25% | 206.02% | -3,300.00% | -217.76% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.95% | -317.61% | 275.39% | -40.45% | -187.53% |